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Introduction
Therapy with ionizing radiation provides a key management
strategy for many epithelial tumour types. Radiotherapy
forms part of the multidisciplinary approach to the treat-
ment of breast cancer, and is now of routine value after
conservative surgery to reduce locoregional recurrence.
However, there are significant limitations of radiotherapy in
many cancers. Some are intrinsically resistant to damage
by ionizing radiation. Moreover, a proportion of cells can
survive irradiation, with treatment inducing their prolifera-
tion to accelerate tumour cell repopulation during radiation
challenge [1]. In total, such events result in a diminished
response to radiation, resistant growth and poor local
control. Knowledge of the molecular mechanisms
employed by tumour cells to evade the inhibitory activity of
radiotherapy is essential if we are to design novel treatment
strategies rationally to improve its effectiveness.
Although various intrinsic and extrinsic factors have been
implicated, the role played by growth factor signal trans-
duction in radiation resistance is particularly fascinating.
Of these, perhaps the most compelling data exist for the
involvement of the epidermal growth factor receptor
(EGFR/c-erbB1/HER1) pathway in determining radiosen-
sitivity. Indeed, there has been a recent flourish of litera-
ture in this area, in part triggered by the availability of
monoclonal antibodies and pharmacological inhibitors that
can block EGFR. In this light, the recent article by Huang
et al. [2] examines the anti-tumour activity of the EGFR-
selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) in
combination with radiotherapy, using several experimental
models of human squamous cell head and neck carci-
noma. Importantly, the study demonstrates superior anti-
tumour potency with ZD1839 plus radiotherapy. It sheds
light on the multiple mechanisms underlying this effect,
notably improved anti-proliferative and pro-apopotic activ-
ity, as well as significant perturbation of angiogenesis,
events that act cumulatively to limit cell recovery after irra-
diation and significantly delay tumour regrowth. Not only
are such data highly supportive of a key role for EGFR in
determining fundamental cancer cell biology and radio-
response, but, importantly, they confirm that anti-EGFR
agents might provide considerable advantage as a
radiosensitizing strategy in cancer management.
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Abstract
Expression of epidermal growth factor receptor (EGFR) has been associated with radioresistance in
cancer. Moreover, tumour cell recovery after irradiation paradoxically occurs, in part, as a result of
activation of EGFR signalling by such treatment. A recent article by Huang, Li, Armstrong and Harari
provides strong rationale for considering the anti-EGFR agent ZD1839 (‘Iressa’) as a radiosensitizing
strategy. With the use of several in vitro and xenograft models of human squamous cell head and neck
carcinoma, ZD1939 was shown to markedly improve radiotherapeutic response, with superior tumour
inhibition and delayed tumour regrowth. Mechanisms underlying this effect included anti-proliferative
and pro-apoptotic activity, with significant perturbation of tumour angiogenesis.
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EGFR occupies a pivotal position in cancer
cell biology
EGFR is established as an important regulator of prolifera-
tion, cell survival, DNA damage repair, cell motility and
invasive capacity. Furthermore, EGFR signalling promotes
angiogenesis, an event essential for cancer cell viability,
tumour growth and metastasis [3]. Not surprisingly, there-
fore, dysregulation of EGFR signalling has been closely
associated with the initiation, growth and progression of
the majority of human epithelial tumour types, including
breast, non-small cell lung, colorectal, head and neck,
ovarian, gastric and pancreatic cancer. EGFR dysregula-
tion, commonly a consequence of receptor or ligand over-
expression and hence enhanced autocrine signalling,
invariably confers aggressive tumour biology in the clinic,
and in some tumour types a poor prognosis [4]. In breast
cancer, EGFR overexpression has been associated with
reduced oestrogen receptor content, advanced clinical
stage and shortened relapse-free survival [5].
EGFR is associated with tumour cell escape
from inhibition by radiotherapy
EGFR dysregulation has been implicated in therapeutic
resistance to diverse agents across many cancer types.
Associations have been noted between EGFR overexpres-
sion and resistance to cytotoxic agents [6] and to anti-hor-
monal agents in breast cancer [5]. Excitingly, an
increasing body of data now indicates that this association
might extend to treatment with ionizing radiation. Although
most of the supportive data in this area have been derived
from cancers that classically overexpress EGFR (notably
including head and neck squamous cell carcinoma), there
is early evidence of equivalence in breast tumour cells, in
which EGFR overexpression can be more modest.
In clinical head and neck cancer, associations have been
reported between EGFR overexpression and radioresis-
tance, increased rate of recurrence after radiotherapy,
poor local control and reduced patient survival [7,8]. Simi-
larly, increased EGFR expression has been directly asso-
ciated with radioresistance in several model systems, with
an inverse correlation reported between magnitude of
EGFR expression and radiocurability using a cohort of
murine tumours, including mammary cancer, in vivo [9]. In
breast cancer in vitro, priming of EGFR signalling with
EGF before irradiation acts to increase radioresistance in
a time- and dose-dependent manner [10].
Intriguingly, studies in vitro, notably those examining the
EGFR-positive MDA-MB-231 breast cancer cell line, have
demonstrated that clinical doses of radiation therapy acti-
vate EGFR signalling [11–14]. Such activation of EGFR
by radiation has been equated with tumour cell prolifera-
tive and cytoprotective effects, explaining not only why
some EGFR-expressing tumour cells survive inhibition but
also the phenomenon of promotion of tumour cell repopu-
lation during a course of radiotherapy. It has been sug-
gested that radiation-induced EGFR activation (and hence
evasion of inhibition and radioresistance) may be particu-
larly obvious in EGFR-overexpressing cells [9]. Both single
and repeated irradiation have been observed to drive
EGFR autophosphorylation, with upregulated EGFR
expression also reported. Priming of expression and proteo-
lytic cleavage of the key EGFR ligand transforming growth
factor-α by irradiation might contribute to this EGFR activa-
tion [12]. There is subsequently phosphorylation of the key
downstream signalling elements Ras, extracellular regulated
(ERK1/2) mitogen-activated protein kinase, p90 ribosomal
S6 kinase and AKT [11,12], with a profile of nuclear tran-
scription factors ultimately stimulated [14].
EGFR inhibitory strategies improve
radioresponse in tumour types including
breast cancer
An obvious therapeutic consequence of these data is that
EGFR blockade might cause radiosensitization. Among the
EGFR-inhibitory strategies, furthest advanced in clinical
study is the EGFR-selective tyrosine kinase inhibitor
ZD1839, which exhibits an acceptable tolerability profile
and promising anti-tumour activity in both experimental
models and cancer patients [15]. Moreover, supra-additive
effects have been observed with this agent in combination
with cytotoxics in many tumour models including breast
cancer, in which improved response has also been reported
when ZD1839 is combined with anti-hormonal procedures
[16]. Clinical studies are continuing in both these areas.
However, the article by Huang et al. is among the first to
demonstrate successfully the modulation of radioresponse
in human tumour cell lines and xenografts by using
ZD1839. The study has employed several human squa-
mous carcinoma cell lines established from biopsies of
head and neck cancer patients with varying EGFR expres-
sion. In all the derived cells in vitro, ZD1839 exerted signif-
icant anti-proliferative activity, inducing arrest in the
radiosensitive G1 cell cycle phase (and depletion of the
radioresistant S phase fraction), as well as the enhance-
ment of radiation-induced apoptosis. Clonogenic survival
assays revealed that reduced cell survival after radiation
was associated with ZD1839. Comparable data demon-
strating cooperative anti-proliferative and pro-apoptotic
activity of ZD1839 and irradiation have similarly been
obtained within experimental non-small cell lung carci-
noma, ovarian, colon and breast cancer [17,18].
Huang et al. have subsequently monitored tumour growth
in athymic nude mice, revealing that ZD1839 also aug-
ments tumour response to radiation in vivo. Combined
treatment with radiation and ZD1839 exhibited improved
tumour growth inhibition and substantially delayed tumour
regrowth in the xenografts examined in comparison with
radiation or ZD1839 alone, with an additive (SCC-6128
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tumour) or synergistic (SCC-1 tumour) growth inhibitory
effect. Substantial effects of radiotherapy plus ZD1839
in vivo, notably long-term tumour regression, have been
confirmed in the handful of additional studies reported for
a range of cancer cell xenografts, including mammary
MDA-MB-468 [17,19]. Huang et al. have shed light on the
underlying mechanism of the potency of radiotherapy plus
ZD1839  in vivo. In addition to the anti-proliferative and
pro-apoptotic effects, a series of elegant experiments
revealed that ZD1839 inhibits the early angiogenic
process by targeting microvascular endothelial cells,
decreasing their cell–cell interaction and disrupting endo-
tube formation, as well as diminishing tumour xenograft-
induced neovascularisation of Matrigel plugs. Significant
anti-angiogenic effects might result from the ability of
ZD1839 to inhibit EGFR-regulated angiogenic growth
factor production by tumour cells, such as vascular
endothelial growth factor, basic fibroblast growth factor
and interleukin-8 [17], and this agent might also directly
block EGFR expressed on endothelial cells.
Studies employing alternative EGFR inhibition strategies in
irradiated tumour cell xenografts as well as in vitro exhibit
equivalent effects to the recent ZD1839 studies from
Huang  et al. Thus, superior anti-tumour activity versus
radiotherapy alone has been reported extensively by this
research group when radiotherapy is combined with the
anti-EGFR antibody IMC-C225 [20]. Comparable data
have also been obtained in various tumour cell lines, includ-
ing breast cancer, using the EGFR-selective tyrphostin
AG1478 [11], EGFR dominant-negative constructs
[21,22] and the irreversible pan-erbB inhibitor CI-1033
[23]. Again, enhanced radiosensitivity seems to result from
the induction of apoptosis, the accumulation of cells in
radiosensitive cell cycle phases, the downregulation of
angiogenic factors and the inhibition of damage repair after
irradiation by the redistribution of DNA repair enzyme [20].
Conclusion
It is clear from the above preclinical studies, exemplified by
this new article from Huang et al., that there is increasing
rationale for considering anti-EGFR agents such as
ZD1839 as a radiosensitizing strategy in cancer manage-
ment. Indeed, data from a novel clinical investigation by
Robert  et al. [24] are highly encouraging, in which all
16 locally advanced head and neck cancer patients
treated with IMC-C225 plus radiotherapy exhibited an
objective response, with no additional toxicity. The results
of continuing clinical trials examining ZD1839 (or
IMC-C225) in combination with radiotherapy in multiple
human malignancies are eagerly awaited.
However, it is important to note that in the study by Huang
et al. tumour regrowth was delayed rather than prevented
by the use of ZD1839 in combination with radiation, and
that pro-apoptotic activity, although clearly enhanced over
radiation alone, was nevertheless relatively modest. Thus,
although there is obviously considerable promise for this
new strategy, our optimism should perhaps be cautious.
Moreover, breast cancer cell studies have revealed addi-
tional complexities that might potentially influence the
outcome of EGFR-targeted inhibitory strategies in combi-
nation with radiotherapy if employed in this disease. For
example, there is increasing evidence that receptors and
signalling pathways other than EGFR might be primed by
irradiation [12,14]. Multiple erbB tyrosine kinase receptor
family members have been observed to be activated indis-
criminately by the irradiation of mammary cells, with HER2
being able to influence EGFR activation in response to
radiation [13]. Moreover, radiation has been shown to be
able to prime several key nuclear transcription factors
(such as CCAAT-enhancer-binding protein and Stat1) in
breast cancer cells in addition to those that are regulated
by EGFR [14]. If we are to employ rationally and gain
maximal benefit from inhibitors such as ZD1839 in breast
cancer, therefore, it is essential that we more fully elucidate
the increasingly complex interrelation between radiation,
recruited signal transduction pathways and cellular
outcome.
Finally, a key contribution to any success of this combina-
tion strategy will be to determine appropriate dosages and
sequence of the treatment, and to define accurately which
patients to treat. The latter could prove particularly prob-
lematic because EGFR overexpression is evident in only
about 40% of breast cancer patients [4,5,25] and ele-
vated expression of the receptor in tumour cells does not
always associate with activity of the pathway or a growth
inhibitory response to anti-EGFR agents [26]. In turn,
experiences in several tumour types with ZD1839 plus
chemotherapy demonstrate that anti-tumour responses
might not require EGFR overexpression [27]. Indeed, in
the study by Huang et al., ZD1839 anti-proliferative
responses were most extensive in SCC-13Y tumours that
exhibited the lowest EGFR expression, whereas in various
tumour cells in vitro, including breast cancer, it is HER2
overexpression, rather than EGFR level, that seems to
associate with increased ZD1839 sensitivity [28]. Clearly
there remains much to be learned about the action of
ZD1839 in clinical breast cancer and its role, if any, in
influencing radiosensitivity.
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